Alpha 2.0
Login Register
» Authors » Andrea Mahr

Andrea Mahr

Explore the profile of Andrea Mahr including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 778
Followers 0
Related Specialties
Oncology
Pharmacology
Allergy & Immunology
Top 10 Co-Authors
Jens Fritsche
Toni Weinschenk
Oliver Schoor
Steffen Walter
Carsten Reinhardt
Veronika Jahndel
Bjorn-Philipp Kloke
Cedrik M Britten
Richard Rae
Dominik Maurer
Published In
Cancer Immunol Immunother
Gene Expr Patterns
Proteomics
Nat Med
J Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
Meyer M, Mahr A, Brewer J, Daniel V, DellAringa J, Goldstone T, et al.
Nat Rev Drug Discov . 2023 Nov; 23(1):1-2. PMID: 38030734
No abstract available.
2.
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy
Kim G, Fritsche J, Bunk S, Mahr A, Unverdorben F, Tosh K, et al.
Sci Transl Med . 2022 Aug; 14(660):eabo6135. PMID: 36044599
T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors...
3.
Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection
Fritsche J, Rakitsch B, Hoffgaard F, Romer M, Schuster H, Kowalewski D, et al.
Proteomics . 2018 Mar; 18(12):e1700284. PMID: 29505699
Immunotherapy is revolutionizing cancer treatment and has shown success in particular for tumors with a high mutational load. These effects have been linked to neoantigens derived from patient-specific mutations. To...
4.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Rini B, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al.
Lancet Oncol . 2016 Oct; 17(11):1599-1611. PMID: 27720136
Background: In a phase 2 study in patients with metastatic renal cell carcinoma, overall survival was associated with T-cell responses against IMA901, a vaccine consisting of ten tumour-associated peptides. In...
5.
The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015
Miller M, Jahndel V, Kutscher S, Mahr A, Rae R, Kloke B
Cancer Immunol Immunother . 2016 Jun; 65(10):1277-87. PMID: 27259506
No abstract available.
6.
The tolerogenic function of annexins on apoptotic cells is mediated by the annexin core domain
Linke B, Abeler-Dorner L, Jahndel V, Kurz A, Mahr A, Pfrang S, et al.
J Immunol . 2015 Apr; 194(11):5233-42. PMID: 25917090
Immunological tolerance is constantly being maintained in the periphery by dendritic cells processing material from apoptotic cells (ACs) in the steady-state. Although research has focused on the uptake of ACs...
7.
Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014
Kloke B, Mahr A, Jabulowsky R, Kutscher S, Rae R, Britten C
Cancer Immunol Immunother . 2014 Dec; 64(7):923-30. PMID: 25548093
No abstract available.
8.
Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013
Kloke B, Rae R, Mahr A, Burkhardt U, Kvistborg P, Britten C
Cancer Immunol Immunother . 2013 Nov; 63(7):749-55. PMID: 24190545
No abstract available.
9.
Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity
Weyd H, Abeler-Dorner L, Linke B, Mahr A, Jahndel V, Pfrang S, et al.
PLoS One . 2013 May; 8(4):e62449. PMID: 23638088
Prevention of an immune response against self-antigens derived from apoptotic cells is essential to preclude autoimmune and chronic inflammatory diseases. Here, we describe apoptosis induced externalization of endogenous cytosolic annexin...
10.
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al.
Nat Med . 2012 Jul; 18(8):1254-61. PMID: 22842478
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total...